On July 15, 2025, the U.S. Food and Drug Administration reported the detection of 7 hydroxymitragynine in Hydroxie 15mg 7 oh sublingual strips. This incident falls under the category of "Other incident" and originated in the United States of America.
The presence of 7 hydroxymitragynine, a compound that has garnered attention for its pharmacological properties, raises concerns regarding the safety and regulatory compliance of the affected product. The detection was made as part of ongoing efforts by regulatory authorities to monitor and ensure the safety of dietary supplements and related products in the market.
Consumers and stakeholders are advised to stay informed about this development and to exercise caution regarding the use of this product. The FDA’s findings underscore the importance of regulatory oversight in the dietary supplement industry, particularly concerning products that may contain unlisted or potentially harmful ingredients.
Further investigations may be conducted to assess the implications of this discovery and to determine necessary actions to protect public health. As this situation develops, updates from regulatory agencies will provide additional context and information.